ADMA Biologics (NASDAQ:ADMA) Sets New 52-Week Low – Here’s Why

Shares of ADMA Biologics Inc (NASDAQ:ADMA) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $13.57 and last traded at $13.59, with a volume of 5366710 shares. The stock had previously closed at $14.32.

Analyst Ratings Changes

ADMA has been the topic of a number of research reports. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Stock Down 5.1%

The firm has a market cap of $3.24 billion, a P/E ratio of 22.65 and a beta of 0.51. The firm’s 50 day moving average is $16.33 and its two-hundred day moving average is $16.64. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same quarter last year, the firm posted $0.46 earnings per share. ADMA Biologics’s revenue was up 18.4% compared to the same quarter last year. As a group, research analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms purchased 7,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. This trade represents a 0.34% increase in their position. The disclosure for this purchase is available in the SEC filing. 3.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. American Century Companies Inc. increased its stake in shares of ADMA Biologics by 8.4% in the 2nd quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock valued at $83,966,000 after purchasing an additional 358,627 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in ADMA Biologics by 24.9% in the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after buying an additional 826,415 shares in the last quarter. Ranger Investment Management L.P. boosted its stake in ADMA Biologics by 49.1% in the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock valued at $43,529,000 after buying an additional 786,865 shares in the last quarter. Boothbay Fund Management LLC bought a new position in ADMA Biologics in the third quarter valued at about $11,334,000. Finally, WINTON GROUP Ltd raised its stake in ADMA Biologics by 302.8% during the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock worth $4,968,000 after acquiring an additional 205,094 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.